JUL SEP OCT NOV DEC SBTi validates Almirall's emission reduction targets for 2030 and its net-zero emissions goal for 2050 Launch of Klisyri® in Luxembourg Launch of the "Moving AheAD" campaign to raise awareness of atopic dermatitis Exclusive rights acquisition of Prometax® in Spain Lebrikizumab receives positive CHMP opinion for moderate-to-severe atopic dermatitis NMPA dossier submission for sarecycline in China AI drug discovery partnership with Absci EC approval of EBGLYSS® (lebrikizumab) for moderate-to-severe atopic dermatitis Launch of EBGLYSS® (lebrikizumab) in Germany Approval of EBGLYSS® (lebrikizumab) in the United Kingdom Collaboration on AI with the BSC and Nostrum Biodiscovery Multi-target alliance with etherna to develop mRNA-based therapies Initiation of phase l study of ALM223, an IL-2muFc for autoimmune diseases New data from POSITIVE, TRIBUTE and TILOT studies for tildrakizumab presented at EADV Bispecific antibody license agreement with EpimAb Biotherapeutics Launch of a new AlmirallShare open innovation call Centrient Pharmaceuticals joins Almirall’s innovation hub Third edition of the "Shedding Light on Psoriasis" campaign FDA accepts supplemental New Drug Application for Klisyri® in 100 cm2 treatment area Positive results from ADjoin long-term extension study of lebrikizumab for atopic dermatitis Positive results of ADvantage study of lebrikizumab presented at EADV